ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "fractures"

  • Abstract Number: 336 • 2016 ACR/ARHP Annual Meeting

    The Risk of Subsequent Osteoporotic Fractures Is Decreased in Patients Experiencing Fracture While on Denosumab

    DL Kendler1, A Chines2, ML Brandi3, S Papapoulos4, EM Lewiecki5, J-Y Reginster6, C Roux7, M Munoz Torres8, A Wang2 and HG Bone9, 1University of British Columbia, Vancouver, BC, Canada, 2Amgen Inc., Thousand Oaks, CA, 3University of Florence, Florence, Italy, 4Leiden University Medical Center, Leiden, Netherlands, 5New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, 6University of Liège, Liège, Belgium, 7Paris Descartes University, Paris, France, 8Hospital Universitario San Cecilio, Granada, Spain, 9Michigan Bone and Mineral Clinic, Detroit, MI

    Background/Purpose:  Osteoporosis is a common, progressive condition leading to increased bone fragility and susceptibility to fracture.  Although osteoporosis therapy decreases fracture risk, fractures while on…
  • Abstract Number: 337 • 2016 ACR/ARHP Annual Meeting

    Denosumab Treatment for 10 Years in Postmenopausal Women with Osteoporosis Was Associated with Substantially Lower Fracture Incidence Relative to Their Baseline FRAX-Predicted Probability

    E Siris1, N Pannacciulli2, PD Miller3, EM Lewiecki4, R Chapurlat5, E Jódar-Gimeno6, NS Daizadeh2, RB Wagman2 and JA Kanis7, 1Columbia University Medical Center, New York, NY, 2Amgen Inc., Thousand Oaks, CA, 3Colorado Center for Bone Research, Lakewood, CO, 4New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, 5Hôpital Edouard Herriot, Lyon, France, 6Hospital Universitario Quirónsalud Madrid, Madrid, Spain, 7University of Sheffield, Sheffield, United Kingdom

    Background/Purpose:  Denosumab is approved for treating postmenopausal women with osteoporosis at high risk for fracture.  The placebo-controlled FREEDOM trial and its active-treatment Extension investigated the…
  • Abstract Number: 345 • 2016 ACR/ARHP Annual Meeting

    The Relationship Between Anti-Cyclic Citrullinated Peptide (anti-CCP) Levels and Bone Mineral Density (BMD) or Fragility Fracture in Patients with Rheumatoid Arthritis (RA)

    Tien-Tsai Cheng1,2, Yin-Chou Chen1,2, Shan-Fu Yu1,2, Han-Ming Lai1,2, Ben Yu-Jih Su1,2, Fu-Mei Su2,3, Wen-Chan Chiu1,2, Chung-Yuan Hsu1,4, Jia-Feng Chen1 and Chi-Hua Ko1, 1Division of Allergy, Immunology and Rheumatology, Chang Gung Memorial Hospital at Kaohsiung, Kaohsiung, Taiwan, 2Chang Gung University College of Medicine, Kaohsiung, Taiwan, 3Chang Gung Memorial Hospital at Kaohsiung, Kaohsiung, Taiwan, 4Division of Rheumatology, Allergy, and Immunology, Chang Gung University College of Medicine, Kaohsiung, Taiwan

    Background/Purpose: To explore the relationship of anti-CCP levels with BMD or fragility fracture in patients with RA Methods: This is a prospective cross sectional study.…
  • Abstract Number: 895 • 2016 ACR/ARHP Annual Meeting

    Incidence of Osteoporotic Mayor Fractures in a Cohort of Patients with Polymyalgia Rheumatica

    Luciano Enrique Pompermayer1, Ignacio Javier Gandino1, Maximiliano José Martinez1, Florencia Beatriz Mollerach1, Marina Scolnik2, Javier Rosa1 and Enrique R. Soriano1, 1Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, 2Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Argentina., Buenos Aires, Argentina

    Background/Purpose: Polymyalgia rheumatica (PMR) is an inflammatory disease associated with older age and long term use of glucocorticoids. As such a high incidence of osteoporosis…
  • Abstract Number: 1023 • 2016 ACR/ARHP Annual Meeting

    Fracture Risk Reduction with Romosozumab: Results of a Phase 3 Study in Postmenopausal Women with Osteoporosis

    F Cosman1, DB Crittenden2, JD Adachi3, N Binkley4, E Czerwinski5, S Ferrari6, LC Hofbauer7, E Lau8, EM Lewiecki9, A Miyauchi10, CAF Zerbini11, CE Milmont2, L Chen2, J Maddox2, PD Meisner12, C Libanati12 and A Grauer2, 1Helen Hayes Hospital, West Haverstraw, and Columbia University, New York, NY, 2Amgen Inc., Thousand Oaks, CA, 3McMaster University, Hamilton, ON, Canada, 4University of Wisconsin–Madison Osteoporosis Clinical Center and Research Program, Madison, WI, 5Krakow Medical Center, Krakow, Poland, 6Geneva University Hospital, Geneva, Switzerland, 7Division of Endocrinology, Diabetes, and Bone Diseases, TU Dresden Medical Center, Dresden, Germany, 8Center for Clinical and Basic Research, Hong Kong, China, 9New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, 10Miyauchi Medical Center, Osaka, Japan, 11Centro Paulista de Investigação Clinica, São Paulo, Brazil, 12UCB Pharma, Brussels, Belgium

    Background/Purpose:  Romosozumab (Romo) is an investigational bone-forming monoclonal antibody that binds sclerostin and has a dual effect, increasing bone formation and decreasing bone resorption. Here,…
  • Abstract Number: 346 • 2015 ACR/ARHP Annual Meeting

    Autoantibodies to Osteoprotegerin Are Independently Associated with Low Hip Bone Mineral Density and Increased Fractures in Axial Spondyloarthritis

    Sizheng Zhao1,2, Barbara Hauser3, Micaela Visconti3, Philip L. Riches3, Stuart H. Ralston3 and Nicola Goodson1,2, 1Musculoskeletal Biology I, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom, 2Department of Rheumatology, Aintree University Hospital, Liverpool, United Kingdom, 3Centre for Genomic and Experimental Medicine, Western General Hospital, Edinburgh, United Kingdom

    Background/Purpose: Axial spondyloarthritis (axSpA) is associated with osteoporosis. However the underlying causes are incompletely understood. Osteoprotegerin (OPG) is a bone protective protein that acts as…
  • Abstract Number: 371 • 2015 ACR/ARHP Annual Meeting

    New Vertebral Fractures after Vertebroplasty: Two Year Results from a Randomised Placebo-Controlled Trial

    Margaret P. Staples1, B Matthew Howe2, Michael Ringler2, Peter Mitchell3, Chris Wriedt4, John Wark5, Peter Ebeling6, Richard Osborne7, David Kallmes2 and Rachelle Buchbinder8, 1Monash Department of Clinical Epidemiology, Cabrini Institute and Monash University, Malvern, Australia, 2Department of Radiology, Mayo Clinic College of Medicine, Rochester, MN, 3Department of Radiology, The University of Melbourne, Royal Melbourne Hospital, Melbourne, Australia, 4MIA Radiology, Melbourne, Australia, 5Department of Medicine, The University of Melbourne, Royal Melbourne Hospital, Melbourne, Australia, 6Department of Medicine, Monash University, Monash Medical Centre, Melbourne, Australia, 7Public Health Innovation, Deakin University, Melbourne, Australia, 8Monash Department of Clinical Epidemiology, Cabrini Institute and Monash University, Melbourne, Australia

    Background/Purpose: We previously reported the results of a randomized participant and outcome assessor blinded controlled trial that found no beneficial effect of vertebroplasty (VP) over…
  • Abstract Number: 382 • 2015 ACR/ARHP Annual Meeting

    Twelve Months after Osteoporosis Associated Fracture – Has Adequate Therapy Been Initiated?

    Christoph Hemmeler1, Sabrina Morell2, Paul Hasler1 and Thomas Gross2, 1Rheumatology, Kantonsspital Aarau, Aarau, Switzerland, 2Traumatology, Kantonsspital Aarau, Aarau, Switzerland

    Background/Purpose: Evidence shows that of ten patients taking medication against osteoporosis one will avoid subsequent fractures, decreasing the risk by > 50 %. On the…
  • Abstract Number: 2084 • 2015 ACR/ARHP Annual Meeting

    Dendritic Cell-Specific Transmembrane Protein (DC-STAMP) Modulates Bone Resorption in Inflammatory Arthritis and Fracture Repair

    Yahui Grace Chiu1, Tzong-Ren Sheu2, Jinbo Li3, Dongge Li4, Michael Thullen2, Brendan Boyce5, Christopher T. Ritchlin6 and Javier Rangel-Moreno7, 1Allergy, Immunology, and Rheumatology, University of Rochester, Rochester, NY, 2Center for Musculoskeletal Research, University of Rochester, Rochester, NY, 3Pathology, University of Rochester, Rochester, NY, 4Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, 5University of Rochester, Rochester, NY, 6Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, 7Allergy, Immunology & Rheumatology, University of Rochester, Rochester, NY

    Background/Purpose: Osteoclasts (OC) direct pathologic bone resorption in osteoporosis and inflammatory arthritis. We previously demonstrated that DC-STAMP (Dendritic Cell-Specific Transmembrane protein), a 7-pass transmembrane protein,…
  • Abstract Number: 2165 • 2015 ACR/ARHP Annual Meeting

    Awareness and Reasons for Lack of Post-Fracture Osteoporosis Therapy: A Survey of Post-Menopausal Women

    Denise Boudreau1, Onchee Yu1, Akhila Balasubramanian2, Jane Grafton1, Heidi Wirtz3, Andreas Grauer3, D. Barry Crittenden3 and Delia Scholes1, 1Group Health Research Institute, Seattle, WA, 2Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, 3Amgen Inc., Thousand Oaks, CA

    Background/Purpose: Osteoporotic fractures cause patient morbidity and increase risk for future fracture. Effective drug therapies for osteoporosis (OP) are available, yet only a minority of…
  • Abstract Number: 2210 • 2015 ACR/ARHP Annual Meeting

    Immunological Dysregulation and Inadequate Hypoxia Adaptation – HIF-Stabilization As Possible Prevention of Fracture Healing Disorders in RA or Immune-Suppressed Patients

    Annemarie Lang1,2,3, Sarah Fuegener2, Paula Hoff1,2, Katharina Schmidt-Bleek4, Timo Gaber1,2 and Frank Buttgereit2, 1German Rheumatism Research Center (DRFZ), Berlin, Germany, 2Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, 3Berlin-Brandenburg School of Regenerative Therapies (BSRT), Berlin, Germany, 4Julius Wolff Institut, Charité University Medicine, Berlin, Germany

    Background/Purpose: Patients suffering from rheumatoid arthritis (RA) are often affected by fracture-healing complications such as increased fracture healing time or non-unions. There is not much…
  • Abstract Number: 3173 • 2015 ACR/ARHP Annual Meeting

    Premature Mortality Due to Fractures in a Population-Based Prospective Cohort Study of 238,673 Older Women and Men

    Lyn March1, Weiwen Chen2, Judy M Simpson3, Fiona Blyth4 and Jacqueline Center2, 1Department of Rheumatology, Northern Clinical School, Institute of Bone and Joint Research, Kolling Institute, University of Sydney & Department of Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia, 2Endocrinology, Osteoporosis & Bone Biology Garvan Institute of Medical Research, St Vincent's Clinical School, UNSW, Darlinghurst, Australia, 3Statistics, University of Sydney School of Public Health, Sydney, Australia, 4Concord Clinical School University of Sydney and Sax Institute, Sydney, Australia

    Background/Purpose: Osteoporotic (OP) fractures and falls are a growing global problem as the population ages. One third of all falls related deaths are attributable to…
  • Abstract Number: 50 • 2014 ACR/ARHP Annual Meeting

    Incidence and Risk Factors for Osteoporotic Vertebral Fracture in Low-Income Community-Dwelling Elderly: A Population-Based Prospective Cohort Study in Brazil. the São Paulo Ageing & Health (SPAH) Study

    Diogo S. Domiciano1, Luana G. Machado2, Jaqueline B. Lopes2, Valéria Caparbo2, Liliam Takayama2, Ricardo M. Oliveira3 and Rosa M. R. Pereira4, 1Rheumatology, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil, 2Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 3RDO Diagnosticos Medicos, São Paulo, Brazil, 4Reumatologia, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil

    Background/Purpose: Vertebral fractures are associated with increased future fracture risk and mortality. No data on incidence of osteoporotic vertebral fracture have been reported in low-income…
  • Abstract Number: 25 • 2014 ACR/ARHP Annual Meeting

    DC-STAMP Modulates Osteoblast Differentiation and Regulates Bone Repair

    Yahui Grace Chiu1, Tzong-Ren Sheu2, Jinbo Li3, Dongge Li1, Michael Thullen2, Brendan Boyce4, Edward Puzas2 and Christopher T. Ritchlin5, 1Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, 2Center for Musculoskeletal Research, University of Rochester, Rochester, NY, 3Pathology, University of Rochester, Rochester, NY, 4Pathology, University of Rochester, Rocehster, NY, 5Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY

    Background/Purpose Patients with osteoporosis and the elderly have an increased risk of bone fracture. Currently, no biomarker is available to assess bone healing status in…
  • Abstract Number: 2471 • 2014 ACR/ARHP Annual Meeting

    Effect of Teriparatide in Patients with Osteoporosis and Rheumatoid Arthritis

    Robin Dore1, Kenneth G. Saag2, Guillermo Valenzuela3, Kathleen Taylor4, Qiu He4, Jahangir Alam4 and Kelly D. Krohn5, 1University of California, Los Angeles, CA, 2Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, 3Integral Rheumatology and Immunology Specialists, Plantation, FL, 4Eli Lilly and Company, Indianapolis, IN, 5DC 5208, Eli Lilly and Company, LLC, Indianapolis, Indiana, Indianapolis, IN

    Background/Purpose:   A common complication in rheumatoid arthritis (RA) is osteoporosis (OP) with increased incidence of fragility fractures. RA is the only disease specifically included…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology